Tao Liang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tao Liang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Piao Cao
Department of Neurology Affiliated Hospital of Zunyi Medical University Zunyi China
3 shared publicationsZhong Luo
Department of Neurology Affiliated Hospital of Zunyi Medical University Zunyi China
3 shared publicationsJian Wang
Department of Neurology, Guizhou Aerospace Hospital Zunyi China
2 shared publications- Zucai Xu
Department of Neurology, Affiliated Hospital of Zunyi Medical University
2 shared publications - Chengyu Ma Pan
Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, China
1 shared publication Chun‐Lin Zhang
Department of Otorhinolaryngology Affiliated Hospital of Zunyi Medical University Zunyi Guizhou China
1 shared publication
Latest Publications
- Open Access
- 12 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70746
Development and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in Adult Generalized Myasthenia Gravis Patients Treated With Efgartigimod
Background: Efgartigimod, a neonatal Fc receptor (FcRn) blocker, is approved for generalized Myasthenia Gravis (gMG), but predictors of early response are unclear. Using minimal symptom expression (MSE) as the therapeutic target, we developed and externally validated a clinical model to predict early MSE response after starting efgartigimod. This efgartigimod‐tailored model estimates the baseline probability of achieving early MSE and may assist in individualized treatment selection at therapy initiation. Methods: We retrospectively analyzed 118 adults with gMG treated at five tertiary centers in China (efgartigimod 10 mg/kg IV weekly ×4). MSE was defined as Myasthenia Gravis–Activities of Daily Living (MG‐ADL) ≤ 1 sustained ≥ 4 weeks; early MSE response was achievement within 4 weeks of initiation. Patients were split into a derivation cohort ( n = 64; three centers) and an external validation cohort ( n = 54; two centers). Candidate predictors included demographics, baseline severity, and laboratory indices. Variables associated with early MSE in univariable analyses entered multivariable logistic regression to construct a nomogram. Discrimination (AUC‐ROC), calibration (curves and Spiegelhalter Z ‐test), and clinical utility (decision curve analysis, DCA) were assessed, with bootstrap internal validation. Results: Early MSE response occurred in 26/64 derivation and 22/54 validation patients. Lower bulbar MG‐ADL (OR 0.633, p = 0.040), higher FVC% (OR 1.042, p = 0.048), and lower IgG (OR 0.795, p = 0.036) independently predicted early MSE response. The nomogram showed strong discrimination—derivation AUC 0.869 (95% CI 0.797–0.941), bootstrap AUC 0.880 (0.806–0.954), and external AUC 0.839 (0.760–0.919)—and good calibration (Spiegelhalter Z : 1.03, p = 0.303; 0.94, p = 0.347; 1.17, p = 0.242). DCA indicated net benefit across thresholds 0.05–0.82, with validation curves mirroring derivation. Conclusions: A three‐factor nomogram (bulbar MG‐ADL, FVC%, and serum IgG) provides an efgartigimod‐specific baseline estimate of early sustained‐MSE response probability, which may help neurologists select appropriate candidates, counsel expected benefit, and tailor follow‐up intensity or alternative escalation strategies. Trail Registration: Chinese Clinical Trial Registry (ChiCTR2500101971)
- 12 January 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (1) , e70746
Open AccessDevelopment and External Validation of a Multivariable Model to Predict Early Minimal Symptom Expression Response in Adult Generalized Myasthenia Gravis Patients Treated With Efgartigimod
Background: Efgartigimod, a neonatal Fc receptor (FcRn) blocker, is approved for generalized Myasthenia Gravis (gMG), but predictors of early response are unclear. Using minimal symptom expression (MSE) as the therapeutic target, we developed and externally validated a clinical model to predict early MSE response after starting efgartigimod. This efgartigimod‐tailored model estimates the baseline probability of achieving early MSE and may assist in individualized treatment selection at therapy initiation. Methods: We retrospectively analyzed 118 adults with gMG treated at five tertiary centers in China (efgartigimod 10 mg/kg IV weekly ×4). MSE was defined as Myasthenia Gravis–Activities of Daily Living (MG‐ADL) ≤ 1 sustained ≥ 4 weeks; early MSE response was achievement within 4 weeks of initiation. Patients were split into a derivation cohort ( n = 64; three centers) and an external validation cohort ( n = 54; two centers). Candidate predictors included demographics, baseline severity, and laboratory indices. Variables associated with early MSE in univariable analyses entered multivariable logistic regression to construct a nomogram. Discrimination (AUC‐ROC), calibration (curves and Spiegelhalter Z ‐test), and clinical utility (decision curve analysis, DCA) were assessed, with bootstrap internal validation. Results: Early MSE response occurred in 26/64 derivation and 22/54 validation patients. Lower bulbar MG‐ADL (OR 0.633, p = 0.040), higher FVC% (OR 1.042, p = 0.048), and lower IgG (OR 0.795, p = 0.036) independently predicted early MSE response. The nomogram showed strong discrimination—derivation AUC 0.869 (95% CI 0.797–0.941), bootstrap AUC 0.880 (0.806–0.954), and external AUC 0.839 (0.760–0.919)—and good calibration (Spiegelhalter Z : 1.03, p = 0.303; 0.94, p = 0.347; 1.17, p = 0.242). DCA indicated net benefit across thresholds 0.05–0.82, with validation curves mirroring derivation. Conclusions: A three‐factor nomogram (bulbar MG‐ADL, FVC%, and serum IgG) provides an efgartigimod‐specific baseline estimate of early sustained‐MSE response probability, which may help neurologists select appropriate candidates, counsel expected benefit, and tailor follow‐up intensity or alternative escalation strategies. Trail Registration: Chinese Clinical Trial Registry (ChiCTR2500101971)
- Open Access
- 17 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (46) , e34215
Facial-onset sensory and motor neuronopathy with myasthenia gravis: A case report
Rationale: Facial-onset sensory and motor neuronopathy (FOSMN) is a greatly rare disease, so far, autopsy evidence that is associated with neurodegenerative. Myasthenia gravis (MG) is an antibody-mediated and complement-involved acquired autoimmune disorder of the post-synaptic neuromuscular junction. There have been few reports about if there is related between the 2. In this study, we present the case of a man who was diagnosed as FOSMN with MG in continuity. Patient concerns: The patient chief complaints were right-side facial numbness and right-eyelid incomplete closure, followed by slurred speech and dysphagia, and the symptoms gradually progressed. The patient serum was positive for anti-AchR and anti-Titin antibodies. Diagnoses: The patient was diagnosed FOSMN with MG. Interventions: The patient symptoms were relieved after pyridostigmine bromide and prednisolone treatment. Outcomes: Symptoms have improved. Lessons: Facial-onset sensory and motor neuronopathy and MG have disparate clinical features. Therefore, we reported a rare case in which the 2 conditions concurrently existed. Immune dysfunction might be the pathogenesis of this association, while there is no definite evidence to support it, further studies are needed.
- 17 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (46) , e34215
Open AccessFacial-onset sensory and motor neuronopathy with myasthenia gravis: A case report
Rationale: Facial-onset sensory and motor neuronopathy (FOSMN) is a greatly rare disease, so far, autopsy evidence that is associated with neurodegenerative. Myasthenia gravis (MG) is an antibody-mediated and complement-involved acquired autoimmune disorder of the post-synaptic neuromuscular junction. There have been few reports about if there is related between the 2. In this study, we present the case of a man who was diagnosed as FOSMN with MG in continuity. Patient concerns: The patient chief complaints were right-side facial numbness and right-eyelid incomplete closure, followed by slurred speech and dysphagia, and the symptoms gradually progressed. The patient serum was positive for anti-AchR and anti-Titin antibodies. Diagnoses: The patient was diagnosed FOSMN with MG. Interventions: The patient symptoms were relieved after pyridostigmine bromide and prednisolone treatment. Outcomes: Symptoms have improved. Lessons: Facial-onset sensory and motor neuronopathy and MG have disparate clinical features. Therefore, we reported a rare case in which the 2 conditions concurrently existed. Immune dysfunction might be the pathogenesis of this association, while there is no definite evidence to support it, further studies are needed.
- Open Access
A case report: Diagnosis and treatment of idiopathic hypertrophic pachymeningitis
A 57‐year‐old man who suffered from a headache for 1 year, accompanied by blurred vision for 7 months and numbness in his left face for 1 week was admitted to the Affiliated Hospital of Zunyi Medical University on May 7, 2022. One year ago, the patient had no obvious precipitating factor of paroxysmal stabbing pain in the whole skull with dizziness, which could be relieved by oneself after lasting for 1–2 min each time, with about 20 episodes per day. The cranial magnetic resonance imaging revealed changes in bilateral frontal lobe ischemic foci, bilateral frontal, ethmoid, sphenoid and maxillary sinusitis, and retinal macular degeneration. After hormone shock treatment, the condition improved. He suffered from headaches again with blurred vision in the right eye 7 months ago and was initially diagnosed with multiple sclerosis. He then was discharged after improvement due to hormone shock therapy. Oral hormone therapy was continued outside the hospital, but he stopped it due to drug side effects (details remained unclear). After cutting off, he developed a headache and visited our hospital once more, the relevant tests were performed and the patient was diagnosed with idiopathic hypertrophic pachymeningitis (IHP). The symptoms were slightly abated after hormone therapy. We hope that through this case report, we can deepen the clinicians' understanding of IHP, and improve the diagnosis rate of the disease through relevant examinations in future clinical work, so that patients can receive timely treatment and the mental pressure and economic burden caused by the disease on patients are reduced.
Open AccessA case report: Diagnosis and treatment of idiopathic hypertrophic pachymeningitis
A 57‐year‐old man who suffered from a headache for 1 year, accompanied by blurred vision for 7 months and numbness in his left face for 1 week was admitted to the Affiliated Hospital of Zunyi Medical University on May 7, 2022. One year ago, the patient had no obvious precipitating factor of paroxysmal stabbing pain in the whole skull with dizziness, which could be relieved by oneself after lasting for 1–2 min each time, with about 20 episodes per day. The cranial magnetic resonance imaging revealed changes in bilateral frontal lobe ischemic foci, bilateral frontal, ethmoid, sphenoid and maxillary sinusitis, and retinal macular degeneration. After hormone shock treatment, the condition improved. He suffered from headaches again with blurred vision in the right eye 7 months ago and was initially diagnosed with multiple sclerosis. He then was discharged after improvement due to hormone shock therapy. Oral hormone therapy was continued outside the hospital, but he stopped it due to drug side effects (details remained unclear). After cutting off, he developed a headache and visited our hospital once more, the relevant tests were performed and the patient was diagnosed with idiopathic hypertrophic pachymeningitis (IHP). The symptoms were slightly abated after hormone therapy. We hope that through this case report, we can deepen the clinicians' understanding of IHP, and improve the diagnosis rate of the disease through relevant examinations in future clinical work, so that patients can receive timely treatment and the mental pressure and economic burden caused by the disease on patients are reduced.
- Open Access
Recurrent bacterial meningitis caused by incomplete Type I inner ear malformation: A case report
The incidence of incomplete partition Type I inner ear malformation is very low; therefore, bacterial meningitis caused by this malformation is also rare. Here, we report a case of such a patient. This case is a young female patient, who is 7 years old, began to have recurrent headaches, and after 5 years, also began to have chest and back pain. The doctor diagnosed meningitis, and the anti‐infection treatment was effective. She was followed up annually and continued to have outbreaks repeatedly for 17 years, but the cause of repeated infection was not found. After a detailed diagnosis and treatment in our hospital, the patient was finally diagnosed with incomplete partition Type I inner ear malformation, resulting in repeated bacterial meningitis. The patient recovered well after surgical treatment, and the symptoms did not recur after 1‐year follow‐up.
Open AccessRecurrent bacterial meningitis caused by incomplete Type I inner ear malformation: A case report
The incidence of incomplete partition Type I inner ear malformation is very low; therefore, bacterial meningitis caused by this malformation is also rare. Here, we report a case of such a patient. This case is a young female patient, who is 7 years old, began to have recurrent headaches, and after 5 years, also began to have chest and back pain. The doctor diagnosed meningitis, and the anti‐infection treatment was effective. She was followed up annually and continued to have outbreaks repeatedly for 17 years, but the cause of repeated infection was not found. After a detailed diagnosis and treatment in our hospital, the patient was finally diagnosed with incomplete partition Type I inner ear malformation, resulting in repeated bacterial meningitis. The patient recovered well after surgical treatment, and the symptoms did not recur after 1‐year follow‐up.
- Open Access
- 28 October 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (43) , e31378
Hereditary motor and sensory neuropathy with SOD1-mutant: A case report
Rationale: Hereditary motor-sensory peripheral neuropathy, or Charot-Marie-Tooth (CMT) Charcot-Marie-Tooth disease is an inherited peripheral neuropathy characterized by progressive limb weakness and muscle atrophy. As the disease progresses, sensory and autonomic involvement may occur. We report a case of CMT associated with SOD1 gene mutation, in order to provide new ideas for clinical disease diagnosis. Patient concerns: A 50-years-old female patient was admitted to the hospital with “progressive weakness of the right lower extremity for 5 years, aggravating, and weakness of the left lower extremity for 4 months”. Diagnosis: The patient was diagnosed CMT. Intervention: Nerve nutrition and rehabilitation therapy were given, but the patient’s condition still did not improve significantly. Outcomes: The improvement of symptoms was not obvious. Lessons: The clinical manifestations and electromyography results of this patient are consistent with the characteristics of CMT. The peripheral nerve-related hereditary gene test found mutation in SOD1. It is possible that this mutation is linked to CMT. The disease is a neurodegenerative disease, that may be slowed by physical therapy and rehabilitation, but could not be healed.
- 28 October 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (43) , e31378
Open AccessHereditary motor and sensory neuropathy with SOD1-mutant: A case report
Rationale: Hereditary motor-sensory peripheral neuropathy, or Charot-Marie-Tooth (CMT) Charcot-Marie-Tooth disease is an inherited peripheral neuropathy characterized by progressive limb weakness and muscle atrophy. As the disease progresses, sensory and autonomic involvement may occur. We report a case of CMT associated with SOD1 gene mutation, in order to provide new ideas for clinical disease diagnosis. Patient concerns: A 50-years-old female patient was admitted to the hospital with “progressive weakness of the right lower extremity for 5 years, aggravating, and weakness of the left lower extremity for 4 months”. Diagnosis: The patient was diagnosed CMT. Intervention: Nerve nutrition and rehabilitation therapy were given, but the patient’s condition still did not improve significantly. Outcomes: The improvement of symptoms was not obvious. Lessons: The clinical manifestations and electromyography results of this patient are consistent with the characteristics of CMT. The peripheral nerve-related hereditary gene test found mutation in SOD1. It is possible that this mutation is linked to CMT. The disease is a neurodegenerative disease, that may be slowed by physical therapy and rehabilitation, but could not be healed.
Report of a family with Huntington's disease
The aim of this article was to analyze the clinical and genetic characteristics of a patient with Huntington's disease and her family. We analyzed the clinical data of a patient with Huntington's disease and her family members in the Department of Neurology of our hospital, drew the genetic pedigree, and used gene fragment analysis to detect and analyze the genes of three people in the family according to the principle of informed consent. The genetic pedigree of the family was consistent with that of autosomal dominant diseases. A total of five people in this family developed the disease, two died, and the main clinical manifestations were dystonia, ataxia, and cognitive impairment. Three people in this family underwent genetic testing, and two exhibited normal genotypes. The cytosine–adenine–guanine trinucleotide (CAG) repeats of the proband were abnormally amplified, and the number of repeats reached 43. The main clinical features of the patient included chronic obscure onset, obvious positive family genetic history, clinical features of involuntary limb movement with cognitive impairment, rapid disease progression, poor treatment effect, and abnormal amplification of CAG repeats as shown through genetic testing. All the above features met the diagnostic criteria of Huntington's disease.
Report of a family with Huntington's disease
The aim of this article was to analyze the clinical and genetic characteristics of a patient with Huntington's disease and her family. We analyzed the clinical data of a patient with Huntington's disease and her family members in the Department of Neurology of our hospital, drew the genetic pedigree, and used gene fragment analysis to detect and analyze the genes of three people in the family according to the principle of informed consent. The genetic pedigree of the family was consistent with that of autosomal dominant diseases. A total of five people in this family developed the disease, two died, and the main clinical manifestations were dystonia, ataxia, and cognitive impairment. Three people in this family underwent genetic testing, and two exhibited normal genotypes. The cytosine–adenine–guanine trinucleotide (CAG) repeats of the proband were abnormally amplified, and the number of repeats reached 43. The main clinical features of the patient included chronic obscure onset, obvious positive family genetic history, clinical features of involuntary limb movement with cognitive impairment, rapid disease progression, poor treatment effect, and abnormal amplification of CAG repeats as shown through genetic testing. All the above features met the diagnostic criteria of Huntington's disease.